Navigation Links
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Date:9/18/2008

atients with long-standing, highly active, inflammatory disease, which complicates the risk estimation. During the long-term open-label trials with HUMIRA, the overall rate of malignancies was similar to what would be expected for an age, gender and race matched general population. With the current knowledge, a possible risk for the development of lymphomas or other malignancies in patients treated with a TNF antagonist cannot be excluded.

All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment, should be examined for the presence of non-melanoma skin cancer prior to and during treatment with HUMIRA.

Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with adalimumab. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. Some of these hepatosplenic T-cell lymphomas with HUMIRA have occurred in young adult patients on concomitant treatment with azathioprine or 6-mercaptopurine used for Crohn's disease. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with HUMIRA cannot be excluded.

In clinical studies with another TNF antagonist, a higher rate of serious congestive heart failure (CHF) related adverse events including worsening CHF and new onset CHF have been reported. Cases of worsening CHF have also been reported in patients receiving HUMIRA. Physicians should exercise caution when using HUMIRA in patients who have heart failure and monitor them carefully. HUMIRA should not be used in patients with moderate or severe heart failure.

The most frequently reported adverse event (>1/10 patients) at least possibly causally related to HUMIRA is injection site reaction (including pain, swelling, redness or pruritus). Other common adverse events (reported by >1/100 patients) at least possibly causally related to HUMIRA include lower
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
6. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
9. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
10. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
11. Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010 2Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010 3Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010 4Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010 5Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010 6Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... , ROYAL PALM BEACH, Fla. , Feb. 4 ... (one in three) suffer from some type of cardiovascular disease. Many ... an exciting sports event like the Super Bowl or World Cup ... comparison of death rates from heart attacks in 2002 and 2001, ...
... with natural tissue , THURSDAY, Feb. 4 (HealthDay News) ... in joints has been developed by U.S. researchers. , ... stimulates bone marrow stem cells to produce natural cartilage, ... therapy can do this, according to the researchers, from ...
... , , NORFOLK, Va. , Feb. 4 ... care for the victims of the devastating earthquake in Haiti ... sent three highly skilled medical teams and over 2 1/2 tons ... two days.  The Operation Smile volunteer teams, which are comprised of ...
... N.J. , Feb 4 Smart Balance, Inc. (Nasdaq: ... on February 25, 2010 , at 9:30 a.m. ET ... 8:30 a.m. ET the same day.  The webcast will be ... call by dialing 1-800-895-0198 from the United States or 1-785-424-1053 ...
... ... how it drives social change , ... Morgantown, WV (PRWEB) February 4, 2010 -- Virtual Global, a leading ... SaaS applications, has launched its new portal for cloud computing information, Cloudipedia. The site, ...
... , SACRAMENTO, Calif. , Feb. 4 ... Romans , CEO and Meg Heim, RN , Vice President ... P.A.D. Task Force Committee on behalf of the Governor of ... and the California Department of Chronic Disease and Injury Prevention (CDPH). ...
Cached Medicine News:Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 3Health News:Nanofiber Gel May Spur Growth of New Knee Cartilage 2Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 2Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 3Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 4Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 5Health News:Smart Balance to Host Webcast/Conference Call on 2009 Fourth-Quarter Results 2Health News:Virtual Global Launches Cloudipedia.com to Help Cloud Computing Newbies 2Health News:Virtual Global Launches Cloudipedia.com to Help Cloud Computing Newbies 3Health News:BioMedix Vascular Solutions, Inc. Invited to Participate in the California P.A.D. Task Force Committee 2
Single piece PMMA lens, AC depth: 4.9, 2 suture holes....
Hydrophobic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
XL STABI Hydrophilic Acrylic Lens....
TRIPODE Hydrophilic Acrylic Lens....
Medicine Products: